Kintsugi
AI NativeAutomating sales tax for companies globally using AI.
Automating sales tax for companies globally using AI.
Published Oct 7, 2026
| Starting Price | Not public (enterprise contract) | Not public (B2B, contact sales) | Not public (enterprise) |
| Primary Fit | Payers/providers wanting voice-based depression/anxiety screening embedded in workflows | Organizations seeking broader vocal biomarkers (mental/cognitive/respiratory) via API/SDK | Organizations combining voice AI with automated outreach/care management workflows |
| Key Technical Positioning | API-first voice screening; public materials reference fairness and governance efforts | Broader biomarker scope and positioning around voice-as-a-physiologic-signal; developer documentation available | Focus on conversational AI and automated outreach integrated with care management |
| Key Limitations | Limited public third-party customer reviews; pricing and validation details not fully transparent publicly | Pricing and biomarker validity depend on population and use case, often vendor-published | May be operationally more complex due to conversational/automation features |
—
Kintsugi and Sonde both provide voice biomarker APIs; Sonde emphasizes a wider biomarker scope. Kintsugi's stated focus is depression/anxiety screening for payer/provider workflows and the vendor references governance practices.
Ellipsis positions more around conversational/agentic care management rather than solely scoring. For buyers seeking automated outreach and workflow automation, an offering focused on conversational workflows may be a better fit; for buyers seeking a focused screening component to integrate into an existing clinical program, a simpler screening API may be preferable.